Inhaled cisplatin for stage IV lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have stage IV non-small cell lung cancer, confirmed by a biopsy.
- You have not yet received any treatment for stage IV lung cancer (previous chemo more than 6 months ago for earlier-stage cancer is okay).
- Your cancer can be measured on scans (RECIST 1.1) and your doctor plans to treat it with pembrolizumab alone or with carboplatin/pemetrexed or paclitaxel.
- You are in good enough health to have a performance status of 0 or 1 (able to be up and about, doing light activities).
- Your lungs work well enough: oxygen level at rest is at least 90%, and breathing tests (FEV1 and DLCO) are at least 50% of what is expected for your age and height.
- You can use a simple handheld inhaler device (like a capsule-based inhaler).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mix of high and low dose radiation along with chemotherapy and immunotherapy for people with locally advanced non-small cell lung cancer. It aims to see if this combination can improve treatment outcomes.
This trial tests injecting cisplatin directly into lung or lymph node tumors for people with stage IV non-small cell lung cancer. It aims to see if this approach is safe and could help control the cancer.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.